Rafferty Asset Management LLC Sells 106,103 Shares of Halozyme Therapeutics, Inc. $HALO

Rafferty Asset Management LLC reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 48.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 113,289 shares of the biopharmaceutical company’s stock after selling 106,103 shares during the quarter. Rafferty Asset Management LLC owned about 0.09% of Halozyme Therapeutics worth $7,229,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in HALO. Congress Asset Management Co. lifted its stake in Halozyme Therapeutics by 8.8% in the first quarter. Congress Asset Management Co. now owns 2,132,707 shares of the biopharmaceutical company’s stock worth $136,088,000 after acquiring an additional 172,971 shares during the period. Dimensional Fund Advisors LP raised its holdings in Halozyme Therapeutics by 4.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,029,160 shares of the biopharmaceutical company’s stock worth $129,478,000 after purchasing an additional 95,600 shares in the last quarter. Northern Trust Corp lifted its position in shares of Halozyme Therapeutics by 8.7% in the 4th quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company’s stock worth $87,386,000 after purchasing an additional 145,617 shares during the period. TD Asset Management Inc boosted its stake in shares of Halozyme Therapeutics by 5.8% during the 1st quarter. TD Asset Management Inc now owns 1,451,842 shares of the biopharmaceutical company’s stock valued at $92,642,000 after purchasing an additional 79,708 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. increased its position in shares of Halozyme Therapeutics by 27.3% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company’s stock valued at $72,107,000 after buying an additional 242,167 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on HALO. Leerink Partnrs lowered shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 13th. HC Wainwright raised their target price on Halozyme Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, August 6th. Leerink Partners lowered Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a research report on Tuesday, May 13th. JMP Securities increased their price objective on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 6th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $67.11.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company’s stock, valued at $46,598,493.69. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 80,000 shares of company stock valued at $4,532,600 in the last 90 days. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Up 0.3%

Halozyme Therapeutics stock opened at $73.18 on Thursday. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $74.07. The company has a market capitalization of $8.56 billion, a price-to-earnings ratio of 16.75, a price-to-earnings-growth ratio of 0.41 and a beta of 1.17. The business’s fifty day simple moving average is $59.88 and its two-hundred day simple moving average is $59.05. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.31. The firm had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company’s revenue was up 40.8% on a year-over-year basis. During the same period last year, the company earned $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.